CRESTOR header image
SERMO DRUG RATINGS

The world's largest dataset of physician perceptions on drugs
350,000 ratings, thousands more added every day

Stethescope image

WHAT IS SERMO DRUG RATINGS?

Living on the SERMO social network, Drug Ratings is the first and only global peer-to-peer drug review system provided exclusively from verified licensed physicians. Drug Ratings is the world’s largest dataset of physician perceptions on drugs. Drugs are rated according to their efficacy, safety, tolerability, accessibility, and adherence. Reviews often also include commentary based on doctors’ real-world experiences.

Ratings was developed by SERMO and our very own physicians. The statistical methodology behind Ratings was developed and verified independently by biostatistics consultants led by Lee-Jen Wei (Blue Null Consulting Group).

Stethescope image

head infographic

AN ENTIRELY NEW WINDOW INTO THE MIND OF PRESCRIBERS

By illuminating what peers think of prescription products, Drug Ratings can impact the success of drugs. Those that already lead the pack will have their market position strengthened by positive remarks and ratings, and others may gain new competitive strengths from comments and reviews. Many physicians wait for early adopters to opine on new treatments or new indications. As Drug Ratings enables the rapid exchange of information between prescribers, it also has the potential to accelerate trial or adoption of new drugs or indications because early adopters can share their experiences sooner and more broadly than ever before.


Ratings can help organizations:
MORE THAN 8/10
UNDERSTAND

why doctors behave as they do


MORE THAN 8/10
COMPARE

your drug to competitor drugs across dimensions



MORE THAN 8/10
GAIN

an early understanding of adoption
and success on newly launched products


MORE THAN 8/10
OBTAIN

actionable insights including gaps in perceived
access, efficacy, tolerability



handshake infographic

PHYSICIANS TRUST EACH OTHERS EXPERIENCES
MOST WHEN IT COMES TO DRUGS

Despite making prescription choices every day, more than half of doctors feel they do not have all the information they would want about a drug before prescribing.1 Physicians have relied on peer opinions, but until SERMO Drug Ratings have not had a consolidated place to find aggregated ratings on treatments. Now doctors do not need to hope the right colleague is available when they have a question about a prescription drug – they can quickly access the combined knowledge of thousands of colleagues right from their pocket.


80%

of doctors report that they trust the recommendations of a very large number of real-world doctors with product experience over the recommendations of a very small number of key opinion leaders/academics.2

69%

of global physicians feel that other doctors have a better understanding of how a drug works in the real world versus pharmaceutical companies, insurance companies, and patients.3


Brain/head cartoon

PHYSICIAN PERCEPTION IS A DRUG’S REALITY & FUTURE

Real-world medicine is messier than what is presented in clinical trials: patients can face issues with adherence and accessibility, and many have comorbidities that complicate treatment. When considering the complexity of actual cases, the perception and experience of other physicians becomes all the more relevant. Perceived product attributes can influence the trial of a drug by physicians and ultimately its market success or failure – even if a drug is accessible, if it is perceived to be inaccessible, the perception can influence doctors not to try it. 

Brain/head cartoon

MORE THAN 8/10


doctors report that the feedback of another physician has changed their perception of a drug,4 and 74 percent believe that drug reviews from other physicians would help inform their prescribing choices.5


RATINGS HAS THE POTENTIAL TO SHIFT SUCCESS AND ACCELERATE ADOPTION

By illuminating what peers think of prescription products, Drug Ratings can impact the success and rate of adoption of drugs. Drugs that already lead the pack will have their market position strengthened by positive remarks and ratings, and other drugs may gain new competitive strengths from comments and reviews. Many physicians wait for early adopters to opine on new treatments or new indications. As Drug Ratings enables the rapid exchange of information between prescribers, it also has the potential to accelerate trial or adoption of new drugs or indications because early adopters can share their experiences sooner and more broadly than ever before.


LEARNING FROM DRUG RATINGS

Industry cannot participate inside Drug Ratings or directly engage with ratings physicians, but SERMO makes the aggregate data available through reports by indication and drug class. Soon, a portal to view and access aggregate data will be made available as well, so industry partners can learn even more from physicians and improve their products and services


1SERMO poll of 2918 doctors from Argentina, Austria, Australia, Canada, Switzerland, Chile, China, Colombia, Germany, Spain, Finland, France, Great Britain, Greece, Hungary, Ireland, Israel, India, Italy, Sri Lanka, Mexico, the Netherlands, Norway, New Zealand, Poland, Sweden, the United States, Venezuela and South Africa. It was fielded in April 2017. The margin of error is ± 2%.

2SERMO poll of 2918 doctors from Argentina, Austria, Australia, Canada, Switzerland, Chile, China, Colombia, Germany, Spain, Finland, France, Great Britain, Greece, Hungary, Ireland, Israel, India, Italy, Sri Lanka, Mexico, the Netherlands, Norway, New Zealand, Poland, Sweden, the United States, Venezuela and South Africa. It was fielded in April 2017. The margin of error is ± 2%.

3SERMO poll of 2918 doctors from Argentina, Austria, Australia, Canada, Switzerland, Chile, China, Colombia, Germany, Spain, Finland, France, Great Britain, Greece, Hungary, Ireland, Israel, India, Italy, Sri Lanka, Mexico, the Netherlands, Norway, New Zealand, Poland, Sweden, the United States, Venezuela and South Africa. It was fielded in April 2017. The margin of error is ± 2%.

4SERMO poll of 2918 doctors from Argentina, Austria, Australia, Canada, Switzerland, Chile, China, Colombia, Germany, Spain, Finland, France, Great Britain, Greece, Hungary, Ireland, Israel, India, Italy, Sri Lanka, Mexico, the Netherlands, Norway, New Zealand, Poland, Sweden, the United States, Venezuela and South Africa. It was fielded in April 2017. The margin of error is ± 2%.

5SERMO poll of 1649 doctors from Argentina, Austria, Australia, Canada, Switzerland, Colombia, Germany, Denmark, Spain, Finland, France, Great Britain, Greece, Hungary, Ireland, Israel, Italy, Mexico, the Netherlands, Norway, Pakistan, Poland, the United States, Venezuela, and South Africa. It was fielded in March 2017. The margin of error is ± 2%.